drug test News
-
Saladax Biomedical, Inc. Acquires Intellectual Property Portfolio for Antipsychotic Drug Tests
Saladax Biomedical, Inc. (Saladax) is pleased to announce that it has acquired a patent portfolio for antipsychotic drug testing from Janssen Pharmaceutica NV. This intellectual property (IP) portfolio includes 17 patent families and has resulted in 33 U.S. patents and 296 patents in ex-U.S. countries. This IP, along with the current Saladax IP, covers the major antipsychotic drugs that are ...
-
NIH/NIDDK Phase II SBIR Awarded Sept 2015
Human induced pluripotent stem cell-derived beta-cells for drug and toxicity ...
-
CELLVIE’s mitochondria treatment has been granted orphan-drug designation from the FDA
The Orphan Drug Act, a law passed in 1983, provides for granting special status to a drug or biological product to treat a rare disease or condition, with the goal being accelerated evaluation and development of promising medical products. This special orphan drug status comes with multiple benefits: Eligibility for market exclusivity for 7 years post approval Tax credits of 50% off the ...
By cellvie Inc.
-
Leading clinical immunotherapies developer Ramy Ibrahim joins bit.bio as Chief Medical Officer
biotech firm bit.bio today announces the appointment of Dr Ramy Ibrahim, MD, as Chief Medical Officer. The addition of a Chief Medical Officer is in line with the company’s plans and commitment to transition into a clinical company. Ramy joins from the Parker Institute for Cancer Immunotherapy where he was Chief Medical Officer and will remain on the board. At the Parker Institute, he ...
By bit.bio
-
Saladax Biomedical and HLS Therapeutics Strengthen Partnership With an Exclusive Distribution Agreement for Canada
Saladax Biomedical, Inc (Saladax) is pleased to announce an exclusive distribution agreement with HLS Therapeutics Inc. (“HLS”) (TSX:HLS) to distribute five MyCare™ Psychiatry Laboratory Assays used to measure the six most commonly prescribed antipsychotic drugs in Canada. The MyCare Psychiatry Laboratory Assays are essential diagnostic tools to monitor a patient’s ...
-
Beckman Coulter Introduces Antipsychotic Drug Testing to Address Unmet Clinical Need for More Than 69 Million People Living with Serious Mental Conditions
Beckman Coulter, a global clinical diagnostics leader, announces it will introduce new antipsychotic drug tests to laboratories and clinicians to address an unmet clinical need for 69 million people with serious mental conditions worldwide. In a new agreement with Saladax Biomedical, Inc., Beckman Coulter will distribute the tests designed to measure blood levels of antipsychotic drugs ...
-
ELITechGroup Microbiology releases a new rapid test to detect resistance to polymyxins.
Among the most clinically significant multidrug-resistant bacteria are carbapenemase-producing Enterobacteriaceae. Because these bacteria usually remain susceptible to polymyxins, interest in this old class of antibiotics has been recently renewed. However, the increasing use of colistin explains why Enterobacterial strains resistant to colistin are increasingly reported worldwide. Currently ...
By ELITechGroup
-
Royal Visitor for Camlab
Camlab Ltd, the laboratory supplies company based at Over, Cambridge, today received a Royal visitor HRH the Duke of Kent. The visit was arranged by UKTI (UK Trade & Investment), the UK Government organisation formed to promote innovation and export growth by UK companies, as part of a tour of companies in the Cambridge area. The Duke toured the Camlab facility and saw the modernisation that ...
-
Agilent Technologies presents 2011 manfred donike award for excellence in sports-doping detection to german and swiss researchers
Agilent Technologies, Inc. (NYSE: A) today announced it has presented the 2011 Manfred Donike Award for scientific excellence in sports-doping testing to Simon Beuck and Nicolas Leuenberger. Agilent sponsors this annual award to recognize distinguished scientific contributions in doping analysis. Award winners are scientists who exemplify the spirit and scientific leadership of doping control ...
-
SEngine Precision Medicine to Present Pan Cancer Data on Predictive Value of PARIS Test at 2021 ASCO Annual Meeting
SEATTLE, April 29, 2021 (GLOBE NEWSWIRE) -- SEngine Precision Medicine, a precision oncology company that pre-tests drugs on live tumor specimens employing its CLIA certified PARIS® Test, today announced that new data from a study summarizing the predictive value of the PARIS® Test across solid tumor cancers will be presented during a poster session (abstract number 2602) at the American ...
-
Adult Stem Cells
Adult stem cells are undifferentiated cells, found throughout the body after embryonic development, which multiply by cell division to replenish dying cells and regenerate damaged tissue. Adult stem cells support tissue and organ turnover throughout life by maintaining a delicate balance between apoptosis and tissue-specific cellular proliferation and differentiation. Adult stem cells reside ...
-
AlveoliX in the Swiss Venture Capital Report 2021
Despite the covid-19 crisis and no mega-rounds of investment in 2020, Biotech start-ups are back at the top! Swiss Biotech startups collected more than CHF 800 million in 2020, an increase of 31% compared to 2019. This is linked to the fact that innovation in drug development is taking place in the long term and, to the constant growing worldwide trend of investments in Biotech. A journey inside ...
By AlveoliX AG
-
Saladax Biomedical, Inc. Announces Global Distribution Agreement With Beckman Coulter, Inc. for Antipsychotic Drug Tests
Saladax Biomedical, Inc. (Saladax) is pleased to announce the signing of a global distribution agreement with Beckman Coulter, Inc. to distribute the MyCare™ Psychiatry Laboratory Assays. The MyCare™ Psychiatry Laboratory Assays measure drug levels of the antipsychotic drugs prescribed to treat patients with serious mental illness (SMI), such as such as Schizophrenia and Bipolar ...
-
New Multi-Organ-Chip project towards vaccine & drug candidate testing for Tuberculosis
TissUse will receive funding from the Bill & Melinda Gates Foundation to develop a human preclinical lung-liver-lymph node co-culture on a HUMIMIC Chip infectable with Mycobacterium tuberculosis. This collaboration will contribute to the development of Tuberculosis vaccine candidates and treatment modalities. TissUse announced today that it has received funding from the Bill & Melinda ...
By TissUse GmbH
-
NYMOX Announces New Marketing Submission for NYMOZARFEX for BPH
Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to announce today that a new formal submission has been made by the Company in Europe for Fexapotide Triflutate for the treatment of benign prostatic hyperplasia (BPH). The trademarked name for the product in the application is NYMOZARFEX (TM). The Marketing Authorization Application (MAA) was submitted to the ...
-
Thermo Fisher Scientific Partners with Mindray on Clinical Chemistry Analyzers for use with Drugs of Abuse Immunoassays
Thermo Fisher Scientific, the world leader in serving science, today announced a partnership with Mindray, a leading global developer, manufacturer and supplier of medical devices, to make available to customers two clinical chemistry analyzers in the United States (U.S.) and Canada for drug screening in clinical and drug court laboratories. "Systematically and reliably testing for drugs of ...
-
CD Formulation Provides Pharmaceutical Testing on Tablet Fragility, Dissolution, and Disintegration
Pharmaceutical testing is a must to ensure that all medications meet the top quality, safety, and performance requirements before they enter the market. CD Formulation’s cGMP-compliant laboratory is well-equipped to identify both the chemical and structural composition of each drug substance. More recently, the company announced to broaden its service range to tablet fragility test, ...
-
NYMOX Provides Current Update
Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to provide a current update on business developments. The Company has corresponded with and has met with the FDA during the past few months. The agency has provided very helpful feedback to the Company. FDA has specified what additional information is required in resubmission of the NDA; and the Company is in the process of preparing the ...
-
Matexcel Provides Expansive Array of Bio-ink Products for Different Applications
Matexcel, a leading innovator in advanced materials and bioengineering, today announced its diverse portfolio of bio-ink products, empowering researchers across various fields to unlock the potential of 3D bioprinting. This comprehensive range, featuring tailored bio-inks for specific applications, paves the way for revolutionary advancements in regenerative medicine, drug discovery, and beyond. ...
By Matexcel
-
Notitia Biotechnologies receives approval from FDA for phase 2A clinical trial in diabetic & prediabetic patients
Notitia Biotechnologies Company has received the Investigational New Drug (IND) approval from the FDA for NBT-NM108, a proprietary formula designed to support the Foundation Guild bacteria in the patient's gut microbiome. The FDA has allowed Notitia to test the drug as a treatment for COVID-19 in patients with type 2 diabetes and prediabetes. Notitia has secured funding for a Phase 2a ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you